Weichert and colleagues demonstrated that HDAC1, HDAC2, and HDAC3 are overexpressed in prostate cancers, whereas increased expression of HDAC1 and HDAC2 correlates with higher Gleason scores. Here, HDAC1 is linked to prostate cancer.